Tiziana Life Sciences (US) (TLSA) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tiziana Life Sciences Ltd. is set to present new data on its pioneering intranasal Foralumab treatment at the American Academy of Neurology’s Annual Meeting, revealing its potential in dampening microglial activation and stabilizing clinical progression in progressive MS. The company’s innovative approach utilizes the only fully human anti-CD3 monoclonal antibody and has shown promising results in modulating immune response and improving safety over traditional intravenous delivery. This presentation underscores Tiziana’s commitment to advancing neuro-immunomodulation therapy, with Foralumab’s Phase 2 trial having begun in December 2023.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.